SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

Zachary Klaassen hosts Alessandro Viti to discuss early oncological outcomes in very high-risk prostate cancer patients using PSMA-PET imaging. Dr. Viti addresses the research question of how surgery ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and dosimetry session and a presentation by Dr. Sabina Dizdarevic discussing eight-year follow-up of patient outcomes and bone ...

Neeraj Agarwal is joined by Wolfgang Fendler to discuss PSMA PET prognostication data. Dr. Fendler's international consortium of 50 sites analyzed 6,000 patients to develop risk stratification models ...

Sam Chang interviews Alice Yu about three practice-changing areas in urothelial carcinoma. Dr. Yu first discusses the NIAGARA trial, which demonstrated improved pathologic complete response, ...

Evan Yu is joined by Atish Choudhury to discuss a first-in-human trial combining EZH2 and PARP inhibition in metastatic castration-resistant prostate cancer. Dr. Choudhury explains that EZH2 is an ...

This review aims to synthesize emerging evidence on the role of adjuvant radiotherapy (RT) following radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC).A randomized trial comparing ...

June 26, 2025 Sacituzumab govitecan (SG) is a TROP2-directed antibody-drug conjugate with a payload of SN-38, a topoisomerase inhibitor. SG monotherapy has demonstrated activity in multiple solid ...

Alon Weizer presented long-term outcomes of UGN-101 chemoablation for low-grade UTUC at SESAUA 2025. In the OLYMPUS trial, 42 patients achieved a complete response after six weekly UGN-101 ...

Neeraj Agarwal is joined by Alicia Morgans to discuss an analysis of baseline PSA levels and clinical outcomes from the ARASENS trial in metastatic hormone-sensitive prostate cancer. Dr. Morgans ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.